I
MRKR icon

INVST’s Marker Therapeutics MRKR Stock Holding History

INVST’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5K Sell
18,000
-11,000
-38% -$16K ﹤0.01% 341
2026
Q1 		$37.7K Buy
29,000
+2,000
+7% +$3.17K ﹤0.01% 332
2025
Q4 		$40.2K Sell
27,000
-2,000
-7% -$2.27K ﹤0.01% 305
2025
Q3 		$25.9K Buy
29,000
+5,600
+24% +$6.91K ﹤0.01% 307
2025
Q2 		$35.8K Hold
23,400
– – ﹤0.01% 296
2025
Q1 		$28.8K Buy
23,400
+3,163
+16% +$5.79K ﹤0.01% 269
2024
Q4 		$62.9K Buy
20,237
+237
+1% +$839 0.01% 244
2024
Q3 		$56.4K Buy
+20,000
New +$79.1K 0.01% 248

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

INVST's MRKR Position: Q2 2026 in Review

INVST reduced its Marker Therapeutics (MRKR) stake by 38% in Q2 2026, selling an estimated $16K and leaving 18,000 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #341.

INVST first reported a position in MRKR in Q3 2024 and has held it in 8 quarters since. The position peaked at $62.9K in Q4 2024. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • INVST held 18,000 shares of Marker Therapeutics worth $26.5K as of Q2 2026.
  • INVST sold 11,000 Marker Therapeutics shares in Q2 2026, an estimated $16K.
  • Marker Therapeutics made up ﹤0.01% of INVST's portfolio in Q2 2026, its #341 holding.
  • INVST first reported a position in Marker Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • INVST's Marker Therapeutics position peaked at $62.9K in Q4 2024.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on INVST's 13F filing for Q2 2026, filed 14 Aug 2026.